Sugi Predict

Sugi Predict / Compounds / SCHEMBL3092977

SCHEMBL3092977

SCHEMBL3092977

NC(=O)[C@H]1c2ccccc2C[C@@H]1O

nearest known ligand 0.46

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.41
▸ GAA P10253 1/20 0.41
▸ AURKA O14965 1/20 0.40
▸ RPS6KB1 P23443 1/20 0.40
▸ ANPEP P15144 1/20 0.40
▸ KDM1A O60341 4/20 0.38
▸ ATM Q13315 1/20 0.38
▸ NAMPT P43490 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ P2RX7 Q99572 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2699779 1.00 ALDH1A1 (0.41) ALDH1A1GAAAURKARPS6KB1ANPEP
SCHEMBL177215 1.00 ALDH1A1 (0.41) ALDH1A1GAAAURKARPS6KB1ANPEP
SCHEMBL10002494 1.00 ALDH1A1 (0.41) ALDH1A1GAAAURKARPS6KB1ANPEP
SCHEMBL4758031 1.00 ALDH1A1 (0.41) ALDH1A1GAAAURKARPS6KB1ANPEP
SCHEMBL177088 1.00 ALDH1A1 (0.41) ALDH1A1GAAAURKARPS6KB1ANPEP
SCHEMBL3327022 0.83 ALDH1A1 (0.41) ALDH1A1GAANAMPTMEN1KMT2A
SCHEMBL8410178 0.83 ALDH1A1 (0.41) ALDH1A1GAANAMPTMEN1KMT2A
SCHEMBL8045772 0.83 ALDH1A1 (0.41) ALDH1A1GAANAMPTMEN1KMT2A
SCHEMBL4283036 0.81 ALDH1A1 (0.41) ALDH1A1GAAANPEPKDM1AATM
SCHEMBL562899 0.81 KDM1A (0.42) ALDH1A1GAAANPEPKDM1AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230033510-A1 Compounds and Methods for Treatment of Visceral Pain ARENA PHARMACEUTICALS, INC. 2023-02-02 — — US claimed
EP-3385252-B1 CANNABINOID RECEPTOR MODULATORS ARENA PHARM INC (US) 2022-09-21 — — EP claimed
US-20210060040-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2021-03-04 — — US claimed
US-10632134-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2020-04-28 — — US claimed
US-20200078358-A1 Compounds and Methods for Treatment of Visceral Pain ARENA PHARMACEUTICALS, INC. 2020-03-12 — — US claimed
CN-110709085-A Compounds and methods for treating visceral pain 艾尼纳制药公司 2020-01-17 — — CN claimed
US-20180354907-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2018-12-13 — — US claimed
EP-3385252-A1 CANNABINOID RECEPTOR MODULATORS Arena Pharmaceuticals, Inc. (US) 2018-10-10 — — EP claimed
EP-3363788-A1 CANNABINOID RECEPTOR MODULATORS Arena Pharmaceuticals, Inc. (US) 2018-08-22 — — EP claimed
US-20170304327-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2017-10-26 — — US claimed
US-9492447-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2016-11-15 — — US claimed
US-20160271127-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2016-09-22 — — US claimed
US-9133187-B2 Serine/threonine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2015-09-15 — — US claimed
US-20150126477-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2015-05-07 — — US claimed
EP-2681215-B1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2015-04-22 — — EP claimed
US-20140206649-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2014-07-24 — — US claimed
EP-2346848-B1 QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2013-02-27 — — EP claimed
US-8318749-B2 Quinazoline derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-11-27 — — US claimed
US-20120214766-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2012-08-23 — — US claimed
US-20100125078-A1 QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-05-20 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214766-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 ALDH1A1 3623/4885GAA 3665/4885AURKA 2601/4885
US-20100125078-A1 QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS SLC6A3, OPRK1, HTR3A ALDH1A1 1385/4885GAA 844/4885AURKA 1265/4885
US-20140206649-A1 CANNABINOID RECEPTOR MODULATORS CNR2, CNR1, OPRL1 ALDH1A1 2692/4885GAA 4343/4885AURKA 4190/4885
US-20160271127-A1 CANNABINOID RECEPTOR MODULATORS CNR2, CNR1, OPRL1 ALDH1A1 2692/4885GAA 4343/4885AURKA 4190/4885
US-20200078358-A1 Compounds and Methods for Treatment of Visceral Pain VIP, FABP2, FABP6 ALDH1A1 603/4885GAA 718/4885AURKA 3718/4885
US-20180354907-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 ALDH1A1 3623/4885GAA 3665/4885AURKA 2601/4885
US-10632134-B2 Cannabinoid receptor modulators CNR1, CNR2, GPR18 ALDH1A1 2571/4885GAA 4513/4885AURKA 2474/4885
US-20150126477-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, GPR18 ALDH1A1 2571/4885GAA 4513/4885AURKA 2474/4885
US-20210060040-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, GPR18 ALDH1A1 2571/4885GAA 4513/4885AURKA 2474/4885
US-20170304327-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, GPR18 ALDH1A1 2571/4885GAA 4513/4885AURKA 2474/4885
US-20230033510-A1 Compounds and Methods for Treatment of Visceral Pain VIP, FABP2, FABP6 ALDH1A1 603/4885GAA 718/4885AURKA 3718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.